Overview
Medullary carcinoma of the thyroid is a neuroendocrine malignancy arising from parafollicular C cells, often associated with elevated calcitonin levels and potential for distant metastasis. It can present with unique syndromes involving other endocrine glands, such as pancreatic nesidioblastosis and hypersecretion of pancreatic polypeptide 1.Diagnosis
Elevated plasma calcitonin levels 1.
Presence of substance P-like immunoreactivity in plasma and tumor tissue 2.
Fasting gastroenteropancreative hormone assays to screen for pancreatic polypeptide hypersecretion in patients with unexplained watery diarrhea 1.
Imaging studies (e.g., CT, MRI) to assess extent of disease and metastasis 1.Management
First-line treatment: Surgical resection of the primary tumor and metastatic sites when feasible 1.
Adjunctive therapy: Long-acting somatostatin analog (e.g., SMS 201-995, 100 micrograms/day) to manage symptoms like watery diarrhea, flushing, and abdominal bloating, and to inhibit pancreatic polypeptide secretion 1.
Symptom control: Addressing specific symptoms such as diarrhea, flushing, and abdominal discomfort with targeted pharmacological interventions 1.Special Populations
No specific data provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts 12.Key Recommendations
Evaluate patients with medullary carcinoma and unexplained watery diarrhea for pancreatic polypeptide hypersecretion via fasting gastroenteropancreative hormone assays (Evidence: Moderate) 1.
Consider long-acting somatostatin analogs for symptom management in patients with concurrent pancreatic polypeptide hypersecretion, particularly for reducing symptoms and normalizing PP secretion (Evidence: Weak) 1.
Prioritize surgical intervention for localized disease to achieve potential curative outcomes (Evidence: Expert opinion) 1.References
1 Jerkins TW, Sacks HS, O'Dorisio TM, Tuttle S, Solomon SS. Medullary carcinoma of the thyroid, pancreatic nesidioblastosis and microadenosis, and pancreatic polypeptide hypersecretion: a new association and clinical and hormonal responses to long-acting somatostatin analog SMS 201-995. The Journal of clinical endocrinology and metabolism 1987. link
2 Skrabanek P, Cannon D, Dempsey J, Kirrane J, Neligan M, Powell D. Substance P in medullary carcinoma of the thyroid. Experientia 1979. link